02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
19:52 , Oct 12, 2017 |  BC Innovations  |  Translation in Brief

Reservoir targets

As priorities in HIV drug development are shifting from suppressing viral replication to clearing the virus completely, attention has turned toward eliminating the latent viral reservoir. Toward that end, a group of Italian researchers has...
21:34 , Aug 3, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: July 2017

New Therapeutic Targets and Biomarkers: July 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during July 2017. Therapeutic targets are defined as any protein, gene or other molecule...
20:34 , Jul 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary Patient sample and mouse studies suggest inhibiting ZBTB7A could help treat lung transplant-associated bronchiolitis obliterans syndrome. In bronchoalveolar lavage samples from lung transplant patients, levels of ZBTB7A were higher in patients who developed donor-specific...
00:30 , Jul 20, 2017 |  BC Extra  |  Tools & Techniques

Team uses NGS to identify new medulloblastoma targets

In a paper published in Nature, researchers at St. Jude Children's Research Hospital, German Cancer Research Center, and other institutions identified new driver mutations from a next-generation sequencing study of patients with medulloblastoma, suggesting the...
22:08 , Apr 4, 2017 |  BC Innovations  |  Distillery Therapeutics

Hepatic; endocrine / metabolic

INDICATION: Hepatic; diabetes Mouse studies suggest inhibiting ZBTB20 could help treat hepatic steatosis and insulin resistance. In a mouse model of diet-induced hepatic steatosis and insulin resistance, liver-specific knockout of ZBTB20 decreased lipid droplet levels in...
19:06 , Feb 22, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs SNPs on nine genomic loci could help predict the risk of CLL. Genome-wide association studies in a total of 4,478 CLL patients and 13,213 healthy volunteers identified associations between the disease and SNPs on...
08:00 , Jan 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: BTB and CNC homology 2 (BACH2)

  Cancer INDICATION: Solid tumors Mouse studies suggest inhibiting BACH2 could help treat solid tumors. In mouse models of melanoma and lymphoma, BACH2 knockout increased tumor infiltration of interferon γ (IFNγ)-expressing CD4+ and CD8+ T cells and decreased...
08:00 , Feb 26, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Mesenchymal stem cell (MSC) screen for oncogenic drivers of undifferentiated sarcomas

Disease models TECHNOLOGY: Cell models An MSC model could help identify therapeutics to treat undifferentiated sarcomas. In isolated MSC-enriched mouse bone marrow cells, p53 depletion plus expression of known sarcoma oncogenes induced sarcomagenesis. In p53-deficient mouse MSCs,...
07:00 , Apr 22, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Ligase IV, DNA, ATP-dependent (LIG4); BTB domain containing 2 (BTBD2); high mobility group AT-hook 2 (HMGA2);...